Menu

Global Blood Therapeutics – $144 Million Shelf‑Takedown

San Diego – March 8, 2017 – Cooley advised the underwriters on Global Blood Therapeutics’ $143.8 million shelf-takedown offering of 5,867,347 shares of common stock, which includes the full exercise of the underwriters’ option to purchase up to 765,306 additional shares of common stock.

Cantor Fitzgerald & Co. acted as sole book-running manager for the offering.

Global Blood Therapeutics, which trades on The NASDAQ Global Select Market as “GBT,” is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat blood-based disorders with significant unmet need.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Charlie Kim  Partner San Diego, Los Angeles
Div Gupta  Partner New York
Kristin VanderPas  Partner San Francisco
Denny Won  Partner San Francisco
Heidi Ausman  Senior Paralegal San Diego
Natasha Leskovsek  Of Counsel Washington, DC
Phil Mitchell  Partner New York
Bill Christiansen  Partner Seattle
Kevin King  Partner Washington, DC
Karen Tsai  Special Counsel Washington, DC
Susan Cooper Philpot  Retired Partner San Francisco
Darren DeStefano  Partner Reston